CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 12 enrolled
Drug / intervention
ARD-101drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05215847
NCT05215847Phase 2Completed
CompareCT.gov

A Phase 2 Open Label Study to Evaluate the Safety, Tolerability, and Efficacy of ARD-101 in Subjects At Least One Year After Bariatric Surgery

Aardvark Therapeutics, Inc.·interventional·Posted Jan 31, 2022·Updated Feb 11, 2025

In Brief

A Phase 2 clinical trial evaluating ARD-101 for Bariatric Surgery and 2 related conditions. Completed, enrolled 12 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate safety and efficacy of twice-daily ARD-101 in subjects at least one year after bariatric surgery (sleeve gastrectomy or gastric bypass).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBariatric Surgery, Obesity, Weight Gain
CountriesUnited States
CollaboratorsUniversity of California, San Diego

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedJan 31, 2022
Enrollment StartMar 1, 2022
Primary CompletionFeb 3, 2023
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 4.4 years ago

Interventions

ARD-101drug

Twice daily, oral administration